鍏充簬 Gene Solutions<\/b><\/p> \n

Gene Solutions 鏄竴瀹朵簹娲茶法鍥界敓鐗╃鎶€鍏徃锛屽湪鍒╃敤鍏堣繘鐨勪汉宸ユ櫤鑳� (AI) 鍜� ctDNA 鎶€鏈彁渚涘垱鏂扮檶鐥囨娴嬭В鍐虫柟妗堟柟闈㈠浜庨鍏堝湴浣嶃€傚叕鍙镐笌涓滃崡浜� 4,500 澶氬鍖婚櫌鍜岃瘖鎵€鍚堜綔锛屾嫢鏈変竴鏀敱绾� 250 鍚嶇敓鐗╁涓撳鍜屾妧鏈汉鍛樼粍鎴愮殑涓撲笟鍥㈤槦锛屽憳宸ユ€绘暟杈� 700 浜恒€�<\/p> \n

Gene Solutions 宸插湪涓滃崡浜氬湴鍖哄彂琛ㄤ簡 50 澶氱瘒鍚岃璇勫鐨勮鏂囷紝骞跺紑灞曚簡 50 澶氶」澶氫腑蹇冪爺绌讹紝鍏惰嚜涓荤爺鍙戞垚鏋滀互鍙婁綅浜庢柊鍔犲潯鍜岃秺鍗楃殑 CAP 璁よ瘉鐨勬柊涓€浠ｆ祴搴� (NGS) 瀹為獙瀹ゅ鍙楄鍙€傞€氳繃灏嗗缁村熀鍥犵粍瀛︿笌浜哄伐鏅鸿兘椹卞姩鐨勬柟娉曠浉缁撳悎锛屽叕鍙歌嚧鍔涗簬鍙橀潻鐧岀棁娌荤枟锛屼护鏇村鐧岀棁鎮ｈ€呭彈鐩娿€�<\/p> \n

\n
1. Hoang, V.-A.N. et al. (2025) 'Real-World utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors,' JCO Oncology Advances, Volume 2. DOI: 10.1200\/OA-24-00084<\/span><\/li> \n
2. Huang, J. et al. (2022) 'Cancer incidence and mortality in Asian countries: a trend analysis,' Cancer Control, 29. DOI:10.1177\/10732748221095955.<\/span><\/li> \n
3. Sharma, R. et al. (2024) 'Temporal patterns of cancer burden in Asia<\/span>, 1990-2019: a systematic examination for the Global Burden of Disease 2019 study,' The Lancet Regional Health - Southeast Asia<\/span>, 21, p. 100333. DOI:10.1016\/j.lansea.2023.100333.<\/span><\/li> \n
4. Kobayashi, S. et al. (2025) 'Japan<\/span> society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing,' International Journal of Clinical Oncology [Preprint]. DOI:10.1007\/s10147-024-02683-0.<\/span><\/li> \n
5. Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development. (2024). In Guidance for Industry [Clinical\/Medical]. FDA Guidances, Content current as of: 01\/17\/2025.<\/span><\/li> \n<\/ol> \n
   \n<\/div>"]; $("#dvExtra").html(content_array[0]);})();